STOCK COMPARISON
Stryker vs Abbott Laboratories: Fair Value & Quality
Both stocks run through our valuation models. Here is how Stryker (SYK) and Abbott Laboratories (ABT) compare, as of Aug 8, 2026.
As of Aug 8, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: Stryker trades at $337 versus a fair value of $186 (-45%), while Abbott Laboratories trades at $108 versus $74.79 (-31%).
Stryker
SYK · USD · Health Care
-45%
upside to fair value
overvalued
Price$337
Fair Value$186
Quality63/100
Abbott Laboratories
ABT · USD · Health Care
-31%
upside to fair value
overvalued
Price$108
Fair Value$74.79
Quality64/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
StrykerAbbott Laboratories
Valuation
36.0×P/E (TTM)27.7×
4.72×P/S (TTM)3.89×
5.32×P/B3.36×
18.8×EV/EBITDA15.1×
1.58×PEG1.47×
1.0%Dividend yield—
$3.44Dividend per share—
Profitability
13%Net margin14%
18%Operating margin13%
15%Return on equity12%
8%Return on assets6%
Growth
3%Revenue growth (YoY)8%
10.8%Avg. growth/yr (3Y)0.5%
11.8%Avg. growth/yr (5Y)5.1%
Balance & size
0.66×Debt / equity0.19×
$119BMarket cap$175B
healthyGrowth qualityhealthy
Abbott Laboratories leads: 5 to 8 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Strykerof which business quality 67 · market factors 49
Abbott Laboratoriesof which business quality 66 · market factors 51
ProfitabilityMargins and returns on capital today
52
50
Quality GrowthAre margins and returns improving?
61
47
CashflowEarnings quality: real cash, not paper profit
75
71
Fin. StrengthBalance sheet, leverage, solvency risk
68
80
InvestmentDisciplined investing over empire-building
66
65
Low VolatilityCalm price path (market factor)
76
83
MomentumPrice trend over the last 3–12 months (market factor)
39
40
52W MomentumDistance to the 52-week high (market factor)
35
34
Net IssuanceBuybacks instead of dilution
86
84
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Stryker
DCF Models$188
Earnings-Based$95.43
Dividend Discount$58.93
Multiples$157
Asset-Based$39.18
Growth DCF$198
Economic Profit$84.35
Growth Earnings$152
26 of 26 models see the stock below the current price.
Abbott Laboratories
DCF Models$70.99
Earnings-Based$29.42
Dividend Discount$39.73
Multiples$69.29
Asset-Based$20.05
Growth DCF$67.02
Economic Profit$37.49
Growth Earnings$64.43
26 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Stryker
Bear $112Fair Value $186Bull $233
$337 = current price (white tick)
Abbott Laboratories
Bear $51.84Fair Value $74.79Bull $94.43
$108 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Stryker · Health Care
Quality score63 · Top 25%
Fair value upside-45% · below median
Abbott Laboratories · Health Care
Quality score64 · Top 25%
Fair value upside-31% · below median
Bottom line
As of Aug 8, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: Stryker trades at $337 versus a fair value of $186 (-45%), while Abbott Laboratories trades at $108 versus $74.79 (-31%).
Abbott Laboratories has the higher quality score (64/100).
See the full analysis →
More comparisons
Popular match-ups from the same sectors, all with fair value and quality score.
Free · Top-25 report
See the undervalued quality stocks every month
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
